Chromoblastomycosis Treatment Market Research Report -Forecast to 2027

Chromoblastomycosis Treatment Market Research Report: by Species (f. Pedrosoi, c. Carrionii, p. Verrucosa, f. Compacta, r. Aquaspersa, c. Funicola), Types (nodular, tumoral, verrucous, plaque), Treatment, Diagnosis, End-User – global forecast till 2027

ID: MRFR/Pharma/4230-HCR | February 2021 | Region: Global | 120 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario:


Chromoblastomycosis is a fungal infection caused by species such as Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola and others. This disease mostly affects the skin and the subcutaneous tissues. Globally, there is about a million type of fungal species, yet nearly 300 are capable of causing infections or disease in humans. Most of these cases are seen in people with compromised immune systems and can occur almost in any part of the body.


A type of fungal infection known as systemic mycosis is affecting the internal organs of the body. During this, fungal infection can spread and affect other organs of the body. The rising cases of immunological diseases is a reason for increased probability of systemic mycosis. Thus, the developing novel treatment for chromoblastomycosis with fewer side effects is the primary objective of manufacturing companies.


The newly launched azoles such as voriconazole and itraconazole, are the gold standard drugs for antifungal therapy. Chromoblastomycosis infections need to be treated with antifungal medication such as itraconazole, terbinafine,  posaconazole, amphotericin B. Often, the treatment for chromoblastomycosis requires surgery to scrape off the infected tissue. The growth of the Chromoblastomycosis treatment market is primarily driven by increasing incidents of fungal infections, rising prevalence of immunological diseases, availability of wide range of products, and increasing awareness about the fungal infections. However, the existence of misbranded drugs and their side effects may slow the growth of the market. The treatment of fungal infections is available in multiple dosage forms such as oral and intravenous medicines. Furthermore, the medications are also available in the form of sprays, creams, solutions, and shampoos.


The global market for chromoblastomycosis treatment is expected to grow at a CAGR of approximately 6.3% during the forecast period, 2017-2023.


Research Methodology


 chromoblastomycosis treatment
Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience



  • Chromoblastomycosis treatment Drug Suppliers

  • Chromoblastomycosis treatment Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The global chromoblastomycosis treatment market is segmented on the basis of species, types, diagnosis, treatment, and end-users.


On the basis of the species, the global chromoblastomycosis treatment market is segmented into Fonsecaea pedrosoi, Cladophialophora carrionii, Phialophora verrucosa, Fonsecaea compacta, Rhinocladiella aquaspersa, Chaetomium funicola, and others.


On the basis of the disease type, the global chromoblastomycosis treatment market is segmented into nodular type, tumoral type, verrucous type, plaque type, and others.


On the basis of the diagnosis, the global chromoblastomycosis treatment market is segmented into blood test, immunodiagnosis, histopathology and mycological examination, tissue biopsy, and others. The immunodiagnosis is classified into enzyme-linked immune sorbent assay (ELISA), and immunodiffusion, and others.


On the basis of the treatment, the global chromoblastomycosis treatment market is segmented into surgery, antifungal drugs, amphotericin B therapy, thermotherapy, laser therapy, photodynamic therapy, adjuvant therapy, and others. The surgery is classified into cryosurgery, curettage, electrodesiccation, surgical excisions, and others. Furthermore, the antifungal drugs are categorized into oral itraconazole, oral terbinafine, posaconazole, isavuconazole, and others.


On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.


Regional Analysis                     


The global chromoblastomycosis treatment market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East & Africa.


The Americas dominate the global chromoblastomycosis treatment market owing to a huge patient population for chromoblastomycosis and well-developed healthcare sector. This disease commonly affects the agricultural workers in rural regions of South America, Central America, and North America.


The European region is the second largest market for the global chromoblastomycosis treatment owing to the rising occurrence of fungal infections among the patients, and advancements in the surgeries procedure and the use of surgical devices. It was estimated that about 20% of these cases were found in countries such as the Czech Republic, Romania, and Finland.


Asia Pacific is the fastest growing region for chromoblastomycosis treatment market due to increasing prevalence of fungal infections, and regional expansion for the development of this market. Japan is considered to exhibit the highest prevalence rate for chromoblastomycosis in the Asia Pacific region.


The Middle East & Africa region contributed the lowest share of the global chromoblastomycosis treatment market, in 2016. Several different Latin American and the African countries, such as Colombia, Gabon, Venezuela, the Dominican Republic, and Cuba, have high prevalence rates for this condition.


Key Players


Some of key the players in the global chromoblastomycosis treatment market are Astellas Pharma (Japan), Biocon Limited (India),  Abbott Laboratories (U.S.), Merck Sharp and Dohme (U.S.), Gilead Sciences (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switzerland), Sanofi (France), F. Hoffman La Roche (Switerzland), Cadila Pharmaceuticals Limited (India),  Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switerzland), and others



TABLE OF CONTENT


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Treatment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chromoblastomycosis Treatment Market, by Species

6.1 Introduction

6.2 Fonsecaea pedrosoi

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Cladophialophora carrionii

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Phialophora verrucosa

6.4.1 Market Estimates & Forecast, 2020 – 2027

6.5 Fonsecaea compacta

6.5.1 Market Estimates & Forecast, 2020 – 2027

6.6 Rhinocladiella aquaspersa

6.6.1 Market Estimates & Forecast, 2020 – 2027

6.7 Chaetomium funicola

6.7.1 Market Estimates & Forecast, 2020 – 2027

6.8 Others

Chapter 7. Global Chromoblastomycosis Treatment Market, by Disease Type

7.1 Introduction

7.2 Nodular Type

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Tumoral Type

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Verrucous Type

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Plaque Type

7.5.1 Market Estimates & Forecast, 2020 – 2027

7.6 Others

Chapter 8. Global Chromoblastomycosis Treatment Market, by Diagnosis

8.1 Introduction

8.2 Blood Test

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Immunodiagnosis

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.3.2 Enzyme-linked immunosorbent assay (ELISA

8.3.2.1 Market Estimates & Forecast, 2020 – 2027

8.3.3 Immunodiffusion

8.3.3.1 Market Estimates & Forecast, 2020 – 2027

8.3.4 Others

8.4 Histopathology and mycological examination

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Tissue Biopsy

8.5.1 Market Estimates & Forecast, 2020 – 2027

8.5 Others

Chapter 9. Global Chromoblastomycosis Treatment Market, by Treatment

9.1 Introduction

9.2 Surgery

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.2.2 Cryosurgery

9.2.2.1 Market Estimates & Forecast, 2020 – 2027

9.2.3 Curettage

9.2.3.1 Market Estimates & Forecast, 2020 – 2027

9.2.4 Electrodesiccation

9.2.4.1 Market Estimates & Forecast, 2020 – 2027

9.2.5 Surgical Excisions

9.2.5.1 Market Estimates & Forecast, 2020 – 2027

9.2.6 Others

9.3 Antifungal drugs

9.3.1 Market Estimates & Forecast, 2020 – 2027

9.3.2 Oral Itraconazole

9.3.2.1 Market Estimates & Forecast, 2020 – 2027

9.3.3 Oral Terbinafine

9.3.3.1 Market Estimates & Forecast, 2020 – 2027

9.3.4 Posaconazole

9.3.4.1 Market Estimates & Forecast, 2020 – 2027

9.3.5 Isavuconazole

9.3.5.1 Market Estimates & Forecast, 2020 – 2027

9.3.6 Others

9.4 Amphotericin B therapy

9.4.1 Market Estimates & Forecast, 2020 – 2027

9.5 Thermotherapy

9.5.1 Market Estimates & Forecast, 2020 – 2027

9.6 Laser therapy

9.6.1 Market Estimates & Forecast, 2020 – 2027

9.7 Photodynamic therapy

9.7.1 Market Estimates & Forecast, 2020 – 2027

9.8 Adjuvant therapy

9.8.1 Market Estimates & Forecast, 2020 – 2027

9.9 Others

Chapter 10. Global Chromoblastomycosis Treatment Market, by End User

10.1 Introduction

10.2 Hospitals & Clinics

10.2.1 Market Estimates & Forecast, 2020 – 2027

10.3 Medical Institutes

10.3.1 Market Estimates & Forecast, 2020 – 2027

10.4 Research Organization

10.4.1 Market Estimates & Forecast, 2020 – 2027

10.5 Others

10.5.1 Market Estimates & Forecast, 2020 – 2027

Chapter. 11 Global Chromoblastomycosis Treatment Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.1 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 U.K

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1 United Arab Emirates

11.5.2 Saudi Arabia

11.5.3 Rest of the Middle East & Africa

Chapter 12 Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

12.3.1 Key Developments

Chapter 13 Company Profiles

13.1 Abbott Laboratories

13.1.1 Company Overview

13.1.2 Diagnosis Overview

13.1.3 Financials

13.1.4 SWOT Analysis

13.2 Astellas Pharma

13.2.1 Company Overview

13.2.2 Diagnosis Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Novartis AG

13.3.1 Company Overview

13.3.2 Diagnosis Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 Merck Sharp and Dohme

13.4.1 Company Overview

13.4.2 Diagnosis/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 Bayer AG

13.5.1 Company Overview

13.5.2 Diagnosis Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.6 Sanofi

13.6.1 Company Overview

13.6.2 Diagnosis Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.7 Pfizer Inc.

13.7.1 Overview

13.7.2 Diagnosis Overview

13.7.3 Financials

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 F. Hoffmann-La Roche Ltd

13.8.1 Company Overview

13.8.2 Diagnosis/Business Segment Overview

13.8.3 Financial Overview

13.8.4 Key Development

13.8.5 SWOT Analysis

13.9 Illumina Inc.

13.9.1 Company Overview

13.9.2 Diagnosis Overview

13.9.3 Financial overview

13.9.4 Key Developments

13.10 Others

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s View Point

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Prediction of Pharmaceutical industry

Chapter 15 Appendix

LIST OF TABLES

Table 1 Chromoblastomycosis treatment Industry Synopsis, 2020 – 2027

Table 2 Chromoblastomycosis treatment Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Chromoblastomycosis treatment Market by Region, 2020 – 2027, (USD Million)

Table 4 Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 5 Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 6 Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 7 Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 8 Chromoblastomycosis treatment Market by End Users, 2020 – 2027, (USD Million)

Table 9 North America Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 10 North America Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 11 North America Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 12 North America Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 13 North America Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 14 US Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 15 US Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 16 US Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 17 US Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 18 US Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 19 Canada Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 20 Canada Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 21 Canada Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 Canada Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 23 Canada Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 24 South America Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 25 South America Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 26 South America Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 27 South America Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 28 South America Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 29 Europe Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 30 Europe Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 31 Europe Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 32 Europe Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 33 Europe Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 34 Western Europe Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 35 Western Europe Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 36 Western Europe Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 37 Western Europe Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 38 Western Europe Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 39 Eastern Europe Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 40 Eastern Europe Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 41 Eastern Europe Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 Eastern Europe Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 43 Eastern Europe Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 44 Asia Pacific Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 45 Asia Pacific Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 46 Asia Pacific Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 47 Asia Pacific Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 48 Asia Pacific Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

Table 49 The Middle East & Africa Chromoblastomycosis treatment Market by Species, 2020 – 2027, (USD Million)

Table 50 The Middle East & Africa Chromoblastomycosis treatment Market by Disease Type, 2020 – 2027, (USD Million)

Table 51 The Middle East & Africa Chromoblastomycosis treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 52 The Middle East & Africa Chromoblastomycosis treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 53 The Middle East & Africa Chromoblastomycosis treatment Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Chromoblastomycosis treatment Market

Figure 3 Segmentation Market Dynamics for Chromoblastomycosis treatment Market

Figure 4 Global Chromoblastomycosis treatment Market Share, by Species 2020

Figure 5 Global Chromoblastomycosis treatment Market Share, by Disease Type 2020

Figure 6 Global Chromoblastomycosis treatment Market Share, by Diagnosis, 2020

Figure 8 Global Chromoblastomycosis treatment Market Share, by Treatment, 2020

Figure 9 Global Chromoblastomycosis treatment Market Share, by End Users, 2020

Figure 10 Global Chromoblastomycosis treatment Market Share, by Region, 2020

Figure 11 North America Chromoblastomycosis treatment Market Share, by Country, 2020

Figure 12 Europe Chromoblastomycosis treatment Market Share, by Country, 2020

Figure 13 Asia Pacific Chromoblastomycosis treatment Market Share, by Country, 2020

Figure 14 The Middle East & Africa Chromoblastomycosis treatment Market Share, by Country, 2020

Figure 15 Global Chromoblastomycosis treatment Market: Company Share Analysis, 2020 (%)

Figure 16 Abbott Laboratories: Key Financials

Figure 17 Abbott Laboratories: Segmental Revenue

Figure 18 Abbott Laboratories: Geographical Revenue

Figure 19 Astella Pharma: Key Financials

Figure 20 Astella Pharma: Segmental Revenue

Figure 21 Astella Pharma: Geographical Revenue

Figure 22 Novartis AG: Key Financials

Figure 23 Novartis AG: Segmental Revenue

Figure 24 Novartis AG: Geographical Revenue

Figure 25 Merck Sharp and Dohme: Key Financials

Figure 26 Merck Sharp and Dohme: Segmental Revenue

Figure 27 Merck Sharp and Dohme: Geographical Revenue

Figure 28 Bayer AG: Key Financials

Figure 29 Bayer AG: Segmental Revenue

Figure 30 Bayer AG: Geographical Revenue

Figure 32 Sanofi: Key Financials

Figure 33 Sanofi: Segmental Revenue

Figure 34 Sanofi: Geographical Revenue

Figure 35 Pfizer Inc.: Key Financials

Figure 36 Pfizer Inc.: Segmental Revenue

Figure 37 Pfizer Inc.: Geographical Revenue

Figure 38 F. Hoffmann-La Roche Ltd: Key Financials

Figure 39 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 40 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 41 Illumina Inc.: Key Financials

Figure 42 Illumina Inc.: Segmental Revenue

Figure 43 Illumina Inc.: Geographical Revenue